HARROW, INC. (HROW): what the price assumes

In the published model solve dated 2026-Q2, anchored at $39.35, HARROW, INC. (HROW) is priced for today's economics sustained for ~12.7 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/HROW

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 5: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 8.4% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.4 years.

How unusual the bet is: high

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Growth

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.9%); the inversion above states its own rate.

Per-Model Detail (n=3)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• Harrow is a specialty ophthalmic pharma that has assembled a branded eye-care portfolio (VEVYE, IHEEZO, TRIESENCE, MAXIDEX, IOPIDINE) by acquiring and licensing drugs rather than discovering them, and guided full-year 2026 revenue of $350 million to $365 million.
• The defining risk is the balance sheet: net borrowings of roughly $448 million against only about $95 million of cash, with operating profit covering barely a tenth of interest, leaving almost no cushion if growth slows.
• Watch VEVYE's prescription trajectory after it passed XIIDRA on a monthly basis, and the TRIESENCE Phase 3 program, both of which the price already credits heavily.

Bull Case

Harrow's structural advantage is a portfolio of branded ophthalmic products that prescribing eye doctors already know and reach for, built through acquisition rather than the decade-long odds of drug discovery. The 10-K lists the franchise plainly, from "MAXIDEX (dexamethasone ophthalmic suspension) 0.1%, a steroid eye drop for steroid-responsive inflammatory conditions" to IOPIDINE and the rest, a stable of established eye-care brands that a generic-only competitor cannot replicate without the same regulatory approvals and physician relationships. In a specialty niche like ophthalmology, that installed base of brands is the moat: distribution into eye clinics, formulary positions, and prescriber familiarity compound over time.

The growth engine is VEVYE, and the data shows it working. The dry-eye drug delivered record prescription performance and surpassed XIIDRA on a monthly total-prescription basis, a genuine share-taking event against an established branded competitor rather than a launch metric. On the strength of the broader portfolio, the company guided full-year 2026 revenue of $350 million to $365 million and adjusted EBITDA of $80 million to $100 million, a step up that, if delivered, begins to put real operating profit underneath the structure.

The pipeline extends the runway beyond today's products. Harrow secured FDA clearance of an IND to support a planned Phase 3 trial of TRIESENCE 40 mg/mL for ocular inflammation and pain following cataract surgery, a defined regulatory path on an asset the company already markets. The bull case is that Harrow is a roll-up that has reached escape velocity on its lead product, with a portfolio deep enough and a pipeline concrete enough to grow into the revenue base the market is paying for.

Bear Case

Start with the balance sheet, because it is where this thesis lives or dies. Harrow carries net borrowings of roughly $448 million against only about $95 million of cash, and trailing operating profit covers barely a tenth of its interest burden. That is not a leverage profile with room to maneuver; it is one that depends on continued growth simply to stay current. The debt history shows the strain: the prior Oaktree loan carried an exit fee and a make-whole premium, with "the exit fee of $3,763,000 ... recorded as a debt discount and recognized as interest expense", and the company has kept tapping the market, most recently pricing $50.0 million of 8.625% senior unsecured notes due 2030. Borrowing at 8.625% to fund a business whose operating profit barely covers existing interest is a treadmill, and the treadmill only works while revenue accelerates.

The dilution compounds the leverage. The share count has been growing at roughly 9% a year, which means existing holders are being diluted at the same time the company is levering up, a combination that signals the business cannot yet self-fund its own growth. Acquiring drug assets with a mix of new debt and new shares is how Harrow built the portfolio, but it is also how the per-share math erodes if the acquired products do not ramp fast enough to outpace both the interest and the dilution.

The valuation makes the fragility acute rather than incidental. No family of valuation method reaches today's price: it is rich on assets, on earnings power, on peer multiples, and even on forward growth. On the company's through-the-cycle margins, the price implies operating profit compounding at its self-funding ceiling for roughly three decades, an assumption that no standard frame supports. The bear case does not require VEVYE to fail. It only requires the ramp to come in slower than the price demands, at which point a company with thin coverage, rising leverage, and a growing share count has no margin for error. Cheap stocks can absorb a stumble; a stock priced beyond every method cannot.

Valuation

The price is making a bet that sits beyond what any standard valuation frame can support. Run today's price against the company's through-the-cycle operating margins and it works out to an extraordinary multiple of normalized operating income, the kind that only makes sense if operating profit grows at its maximum self-funding rate for something like thirty years. Treat that horizon as a direction rather than a measurement, because it rests on a single solve with depressed trailing margins, but the direction is unambiguous: the price prices a long, uninterrupted compounding story.

Every lens agrees the price is rich. The asset-value methods, the earnings-power methods, the peer multiples, and even the forward-growth methods all land below today's level. That is the rare case where there is no family pointing at a gap to defend, because no family reaches the price at all. When even the growth-DCF, the method most generous to a fast-growing company, sits below the price, the market is paying for an outcome more aggressive than the most optimistic standard method will credit. The interpretation is not that the methods are too conservative; it is that the price has detached from what the methods can frame.

Solvency is the load-bearing risk in the close. Net borrowings of about $448 million against roughly $95 million of cash, with operating profit covering interest only a fraction of a single time, is a balance sheet running with almost no cushion. The 8.625% coupon on the latest notes is the market's own read on the credit risk. The full-year 2026 adjusted EBITDA guidance of $80 million to $100 million is the number that has to be hit, and then hit again, for the leverage to become manageable. The valuation does not rest on any one multiple. It rests on whether a thinly-covered, dilutive, debt-funded roll-up can grow into a price that no method supports before the cost of its own capital catches up with it.

Catalysts

The product ramp is the catalyst that matters most, because the price needs the revenue to keep accelerating. VEVYE's prescription momentum is the cleanest read: it surpassed XIIDRA on a monthly total-prescription basis and posted record performance, and whether that share-taking continues will drive whether the company hits its full-year 2026 revenue guidance of $350 million to $365 million. A first-quarter revenue miss against that ramp, even with the guidance reaffirmed, is the kind of stumble a stock priced this richly cannot easily absorb.

The pipeline and the financing calendar are the other two threads. The TRIESENCE 40 mg/mL Phase 3 program, cleared to proceed by the FDA, is a defined regulatory event that extends an existing product. On the financing side, the company's recent $50.0 million 8.625% notes due 2030 show it is still actively managing a heavy debt load, so any further issuance, refinancing, or change in terms is a direct signal about how the market is pricing its credit. The next earnings print, set against the adjusted EBITDA guidance of $80 million to $100 million, is where the growth-versus-leverage race becomes legible.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• LGND (LIGAND PHARMACEUTICALS INCORPORATED)
• FY2025 10-K: …us indirectly by affecting the ability of our partners and others with whom we do business to meet their obligations to us and reduce our ability to realize the value of the consideration provided to us by these other companies in connection with their licensing of our products. We face competition in acquiring…
• FY2025 10-K: 25 % of sales revenue of PeliCRM197 above $ 3 million and 35 % of all PeliCRM197 licensing revenue in perpetuity. The considerations were recognized as contingent consideration under the loss recovery model and they will be measured based on the gain contingency model under ASC 450, Contingencies , and thus, will be…
• IOVA (IOVA)
• FY2025 10-K: …Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established…
• FY2025 10-K: …amount of time, effort, and money. Such post-approval requirements may also limit the commercial prospects of our products and product candidates. We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth. Our operations are dependent upon the…
• LQDA (LIQUIDIA CORPORATION)
• FY2025 10-K: In addition to the commitments described above, we are party to other commitments, including non-cancelable leases and long-term debt, which are described elsewhere in these notes to the consolidated financial statements. F-37 Table of Contents ​ 15. Segment Information We operate as a single business segment focused…
• FY2025 10-K: …new skilled personnel. Our ability to continue our operations and manage our potential future growth depends on our ability to hire and retain suitably skilled and qualified employees, including those in senior management, in the long-term. Due to the specialized nature of our work, there is a limited supply of…
• ADPT (ADPT)
• FY2025 10-K: $ ( 159,595 ) $ ( 225,304 ) *Non-significant segment expenses for Immune Medicine. (1) Segment information for the year ended December 31, 2023 is presented on a comparable basis to that of the 2025 and 2024 periods and is based on judgments and allocation methods from our organizational changes implemented during…
• FY2025 10-K: …to generate and characterize similar data to our known data for the purpose of identifying and developing products or services that could compete with any of our products or services. Further, immune medicine is being pursued by several biotechnology companies as well as by large-cap biopharmaceutical companies. Many…
• AUPH (Aurinia Pharmaceuticals Inc.)
• FY2025 10-K: …measures, legislative developments at the E.U. or member state level may result in significant additional requirements or obstacles. The delivery of healthcare in the E.U., including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for…
• FY2025 10-K: …an entity's expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The guidance is effective for annual reporting periods beginning after December 15, 2026 and…
• RCUS (RCUS)
• FY2025 10-K: …liabilities as of December 31, 2025 and 2024. 107 Table of Contents Note 18. Business segment We operate and manage our business as one reportable and operating segment, which is the business of developing and commercializing highly differentiated therapies that have a meaningful impact on patients. Our chief…
• FY2025 10-K: …other similar companies; • results from our ongoing clinical trials and future clinical trials with our current and future investigational products or of our competitors; • changes in our projected operating results that we provide to the public, our failure to meet these projections or changes in recommendations by…
• VCEL (VERICEL CORPORATION)
• FY2025 10-K: …Parts B and D, respectively. These measures may materially and adversely affect the price we receive for any of our products. In the U.S., individual states have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient…
• FY2025 10-K: …development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with FDA regulations and approval requirements, as well as the ability to grow the Company's business…
• ANAB (ANAB)
• FY2025 10-K: …by the U.S. Food and Drug Administration ("FDA") and/or by foreign regulatory authorities outside of the jurisdiction where the study was being performed; • the potential benefits and advantages of our product candidates and approaches versus those of our competitors; • the success of competing therapies that are or…
• FY2025 10-K: …our commercialization. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.